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A BST R A C T 
Cardiovascular disease, including hypertension, accounts for almost 50% of the deaths in 
patients with end stage renal disease (ESRD) on hemodialysis (HD) yet hypertension 
remains very poorly controlled in this population. The purpose of this study was to 
retrospectively compare control of hypertension in hemodialysis (HD) patients when 
extracellular volume (ECV) was assessed and managed by clinical parameters and 
physical assessment data alone with control of hypertension when data from blood 
volume monitoring (BVM) technology was also used to assess and manage ECV in a 
freestanding outpatient hemodialysis unit. The main cause of hypertension in the ESRD 
population has been identified as increased ECV most likely secondary to increased 
interdialytic weight gain and failure to attain and maintain patient’s dry weight. HD 
nurses often employ clinical parameters along with physical examination to determine a 
patient’s pre, intra, and post dialytic fluid status and this approach can have a high index 
of error. BVM technology is being used in many hemodialysis units to assist with 
assessment of ECV. A comparative retrospective chart review was used to collect data for 
this project. A descriptive, cross-sectional design was employed to answer the 
question:“Are hypertensive hemodialysis patients who dialyze in a freestanding dialysis 
unit, where BVM technology is utilized, more likely to be normotensive as defined by a 
pre dialysis blood pressure of less than 140/90 and post dialysis blood pressure less than 
130/80”? A pilot study was conducted to determine if the patient population and data 
were available in existing patient records for extrapolation. Approval for the study was 
obtained from the University IRB. A convenience sample was obtained from the records 
of patients meeting the inclusion criteria. Variables were measured and analyzed using 
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descriptive statistics such as sampled paired T-test to compare pre and post BVM 
systolic, diastolic blood pressures, intradialytic weight gain, serum Albumin and sodium 
levels, and hemoglobin. A p-value of 0.05 was assigned for statistical significance. Data 
analysis showed there were statisticaly significant differences in the pre dialysis systolic 
blood pressure, post BVM, and the serum sodium pre and post BVM when the two 
groups were compared These statistically significant findings support a correlation 
between reduction in the HD patient’s ECV and improved blood pressure control. The 
reduction of pre-dialysis SBP was significant because many patients on hemodialysis 
have systolic hypertension that may or may not coexist with diastolic hypertension. The 
findings of this study may be used to formulate a protocol to be used in the HD units 
where the BVM is available. The protocol would rely on accurate nursing assessment of 
clinical parameters, patient verbalizations of symptoms, and the routine use of the BVM 
in order to continuously assess the patient’s fluid status. Future research 
recommendations include conducting the study in a population closer to the national 
sample, a study where glucose readings and /or hemoglobin A1C levels are measured to 
assess the impact of glucose on ECV, and which antihypertensive class of medication 
works best with BVM technology to effectively manage hypertension in this population. 
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C H APT E R 1: IN T R O DU C T I O N 
Outline for Thesis 
This chapter will discuss the current assessment models and management of HTN 
and ECV in the HD patient. The purpose of Chapter 2 is to present the research reports 
and evidence based recommendations. Chapter 3 will describe the design and 
implementation of the project. Chapter 4 will present and discuss the results and Chapter 
5 will present conclusions and suggestions for future studies.  
Problem/Significance 
According to the United States Renal Data System (USRDS; National Institute of 
Diabetes and Digestive and Kidney Diseases [NIDDKD], 2008) there were 360,000 
ESRD patients in the U.S. of which 93% receive hemodialysis and 7% receive peritoneal 
dialysis (PD). Hypertension (HTN) is the second leading cause of chronic kidney disease 
(CKD) and ESRD (NIDDKD, 2008) yet HTN remains widely uncontrolled even once the 
patient makes the transition to ESRD (Aggarwal, 2003). It is estimated that 87% of 
diabetic HD patients and 67% of non-diabetic HD patients have inadequate blood 
pressure control (Mailloux, 2001). Hypertension is the leading and undisputed leading 
cause of cardiovascular disease (CVD; Zoccali, Mallamaci, & Tripepi, 2000). In the 
ESRD population, CVD is the predominant cause of morbidity and mortality.  
The mortality rate for dialysis patients in the United States is 20 % approximately 
50% of which is from CVD (Hlebovy, 2006) The most common cause of hospital 
admissions for HD patients is CVD related diagnoses. CVD related diagnoses account for 
49% of chronic and 40% of acute admissions of that pulmonary edema being the most 
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common admitting diagnosis (Hlebovy, 2006). The use of antihypertensive medications 
is not as effective in CKD Stage 5 and ESRD because the cause hypertension in this 
population is most likely camouflaged volume retention (Hlebovy, 2006). The use of 
Thiazide and Loop diuretics in late stages of CKD and ESRD has a diminished effect 
secondary to the severely decreased glomelular filtration rate (GFR) and potassium 
sparring diuretics are contraindicated due to the increased risk of hyperkalemia (Izzo, 
Sica, & Black, 2008). 
The pathophysiological cause of HTN in ESRD, after secondary causes have been 
ruled out, is extracellular volume (ECV) expansion (Hlebovy, 2006). Total body water is 
contained within 2 compartments: intracellular (within the cells) and extracellular 
(outside the cells). The intracellular compartment holds about 60% of total body water 
and the ECV holds about 40% of which 20% is within the plasma volume (Mitchell, 
2002). ECV is the fluid contained in the interstitial, transcellular, and the intravascular 
spaces (Mitchell, 2002).  
As renal failure worsens, the ability of the kidneys to balance sodium and water 
output dramatically decreases leading to sodium and water excess that may abet HTN by 
expanding the ECV and increasing ventricular wall stress (cardiac output) during systolic 
ejection. The foundations of managing HTN in HD patients are achieving appropriate dry 
body weight through dialysis, interdialytic fluid restriction, attending HD sessions, 
adhering to prescribed dietary guidelines and medication therapy (Denhaerynck et al., 
2007).  
 3 
Background of Hypertension in H D Patients 
Hypertension is estimated to be present in up to 80% of ESRD patients sometimes 
as the primary cause of renal failure but more often as a secondary complication ESRD 
where inaccurate patient assessment of ECV status or patient complications during HD 
(i.e. hypotensive episodes) leads to decreased fluid removal (Savage, Fabbian, Gibbs, 
Tomson, & Raine 1997). The result of decreased fluid removal is increased ECV which 
may lead to hypertension. Hlebovy (2006) concluded that 90% of HD patients could 
become normotensive by lowering the ECV and focusing on the patient’s dry weight.  
Assessment of the patient’s fluid status is based on the patient’s dry weight (DW). 
DW, as it pertains to the ESRD population, is defined as the lowest weight a patient can 
tolerate without the development of symptoms (i.e. cramping) or hypotension in the 
absence of antihypertensive medications (Rodriguez, Domenici, Diroll and Goykhman, 
2005). Appropriate DW is directly correlated with control of blood pressure and notably 
increased HD patient survival rates (Hlebovy, 2006).  
In many dialysis units, DW is assessed by the presence or absence of clinical 
parameters and physical exam such as dyspnea, headache, periorbital and pre-tibial 
edema, postural dizziness, cramps, hypotension and hypertension. Raimann, Lui, Ulloa, 
Kotanko, and Levin (2008) found that none of these clinical parameters and physical 
findings were sufficiently specific or sensitive to DW and fluid assessment and may 
exhibit a large margin of error due to patient variability.   
The problem with DW assessment based on purely clinical grounds is that dry 
weight cannot be assessed by a single parameter (Locatelli et al., 2004). Factors such as 
the patient’s residual renal function as evidenced by urinary output, other sources of fluid 
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loss such as diarrhea and emesis, and interdialytic well being such as appetite and energy 
levels, should be incorporated and reassessed at least every 2 weeks to assure the 
patient’s post dialysis weight reflects an accurate DW and management of ECV 
(Locatelli et al., 2004). Jaeger and Mehta (1999) studied the current methods of ECV/DW 
assessment method of dry weight and concluded that it was difficult to determine whether 
a patient was over-hydrated or under-hydrated even when these assessment methods are 
properly employed.  
Four emerging technological methods that show promise are being used and have 
gained popularity in recent years within the HD community. These methods include the 
use of biochemical markers, vena cava diameter, bioimpedence, and blood volume 
monitoring (BVM). Of the 4 methods discussed, BVM, which has been available since 
1992, has become the most widely used and accepted method of assisting in the 
determination of a patient’s ECV fluid status in both in- and outpatient settings 
(Rodriguez, Domenici, Diroll and Goykhman, 2005). 
BVM determines ideal body weight non-invasively by directly measuring the 
change in blood volume by monitoring the fluid volume and oxygenation in the intra-
vascular space. BVM monitors the patient’s real time hematocrit because red blood cells 
(RBC) are too large to pass through the dialyzer. RBC mass remains constant during the 
dialysis treatment (Donauer, 2004) but hematocrit levels have an inverse relationship 
with hydration status within the human body. An increased hematocrit, per BVM, is 
highly representative of reduction of the ECV and the decreased hematocrit represents 
increased in ECV (Donauer, 2004). 
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The BVM displays a picture of the patient’s volume status based on the variability 
of the patient’s real time hematocrit and Oxygen levels. The clinician is able to adjust the 
DW and rate of fluid removal by monitoring the patient and BVM every 15 minutes. The 
BVM has the ability to notify the clinician of impending intradialytic complications such 
as hypotension and cramping by displaying changes in the patient’s hematocrit and 
oxygenation levels for which the clinician has been trained to observe and intervene 
appropriately (Donauer, 2004).  
Many dialysis personnel involved in the assessment of the patient’s BP and fluid 
status rely on the patient’s past post dialysis weights, complaints, or lack of complaints of 
symptoms such as muscular cramping, post HD fatigue, and pre-dialysis blood pressure 
to determine the patient’s target fluid removal. Some clinics use BVM along with clinical 
parameters and physical exam to assist in determining the patient’s ECV status. The an 
education of Nephrology nurses and ancillary staff such as certified dialysis technicians 
on the clinically significant link between HTN and ECV status may lead to an improved 
knowledge base and eventually improved overall outcomes. 
Hypertension in H D Patients: The Nursing Community Takes Action 
The reported prevalence of HTN in HD patients is estimated to be between 50%-
90% (Purcell, Williams, & Walker, 2004). Antihypertensive medications do not reduce 
the blood pressure effectively in this population because the most likely etiology of HTN 
in HD patients is increased ECV. Therefore The American Nephrology Nurses 
Association (ANNA) viewed fluid management as an area of concern and convened a 
special interest group (SIG) in 2004. The goal of the SIG was “to supply information 
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about accurate dry weight measurement and the effects of inaccurate measurement “ to 
the nephrology nursing community. 
The objectives of the SIG included reviewing the long-term complications of 
hemodialysis related to fluid volume excess and fluid volume deficit and to assess the 
effectiveness of the BVM as a tool to assist in obtaining the ideal DW. The SIG 
concurred BVM would be helpful in managing ECV but stated more studies were needed 
(Purcell, Williams, & Walker, 2004). CVD is the leading cause of morbidity and 
mortality in the HD patient. Long term HTN not only affects the patient’s morbidity and 
mortality but also the patient and their families/ loved ones quality of life. Another issue 
is that long term HTN may hinder the patient’s chances of possible kidney (living or 
cadaver) transplant as the heart of a patient with uncontrolled HTN may be enlarged and 
have left ventricular hypertrophy which may hinder cardiac output and may not have 
enough cardiac output to sustain the needed blood flow to the transplanted kidney.  
Nephrology practitioners now have 4 decades of clinical and physical assessment 
knowledge and, in some facilities, the assistance of technology to manage fluid volume 
and HTN. Improving BP control in this vulnerable population is a collaborative effort 
among the nursing, medical, dietary, and social work providers involved in the patient’s 
care. The ANNA SIG on fluid management position statement announced it is time for 
nephrology nurses and the nephrology industry to accept accountability and include fluid 
management (clinical parameters, physical exam and available tools such as BVM) as 
part of the HD standards of care which may be located within the National Kidney 
Foundation’s Kidney Dialysis Outcomes Quality Initiatives (NKF-KDOQI) guidelines 
(2006).  
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The SIG continued by stating the goal of fluid management should be in line with 
dialysis pioneers such as Dr. Scribner’s who defined DW as the post dialysis weight that 
allows the BP to remain normal (less than 130/80 mm/hg) until the next dialysis session, 
without the use of antihypertensives, and despite interdialytic weight gain (NKF-KDOQI, 
2006). In 1961 Dr. Belman Scribner, the father of chronic dialysis, made the observation 
HTN may be controlled by low sodium diet and fluid removal during HD (Shaldon, 
2002). The first patients were dialyzed for 6-8 hours three times a week. The long 
dialysis sessions allowed for the removal of increased fluid volume and toxin removal. In 
the first 3 out of 4 long-term HD patients treated by Dr. Scribner, anti-hypertensive 
medications were stopped secondary to hypotensive episodes (Shaldon, 2002).  
Objectives/Aims 
This review of the current state of science revealed the potential benefit of 
managing HTN in the HD patient by assessing the ECV status and attaining euvlomemia 
using clinical parameters and BVM technology as an adjunctive tool.  Effective HTN and 
fluid circumspection is directly related to decreased CVD associated morbidity and 
mortality. The NKF-KDOQI guidelines regarding the management of HTN in HD 
patients emphasize attention to the patient’s fluid status (Clinical Practice Guidelines, 
2006). Kidney Disease: Improving Global Outcomes (KDIGO), the international 
consortium HTN management guidelines recommend gradual reduction of the patient’s 
DW as antihypertensive medications are withdrawn. Therefore, HTN management in the 
HD patient through approximating the ECV status is recommended by both the KDOQI 
and KDIGO guidelines in attempt to decrease CVD associated morbidity and mortality. 
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1. Provide data to support the use of tools such as the BVM will effectively manage 
the ECV thereby assist in control of hypertension in HD patients. 
2. Improving the patient and/or their families/loved ones quality of life by 
decreasing CVD associated morbidity and mortality by effectively controlling 
ECV status. 
This study aims to answer the question “Are HD patients who dialyze in a 
freestanding HD unit where BVM technology is used as an adjunctive tool along with 
assessment of clinical parameters more likely to be normotensive (BP < 140/90 pre-
dialysis. 130/80 post-dialysis) secondary to achieving and maintaining an adequate dry 
weight?” The feasible, interesting, novel, ethical, and relevant (FINER) criteria was used 
to determine the research question. The author deems the project to be feasible based on 
the availability and appropriateness of records on which to evaluate the impact of the use 
of the BVM in addition to clinical parameters The completed project will contribute to 
the literature, which supports the belief that HTN may be managed in HD patients with 
appraisal of clinical parameters and fluid management utilizing BVM technology. This 
project is ethical as the researcher adhered to the ethical principles of respect for persons, 
beneficence, and justice as outlined in the Belmont Report. Lastly, the relevance of this 
project has been attested by previous studies and reports that document that a large 
percentage of HTN is HD patients secondary to excess ECV status. 
Variables 
The patient records reviewed were records of hypertensive HD patients in which 
secondary causes of HTN have been excluded and reflected use of BVM within the past 
12 months. The records were reviewed to obtain pre and post dialysis weights, blood 
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pressure measurements, albumin, hemoglobin and sodium levels. The identified variables 
were pre and post intervention systolic and diastolic blood pressure, interdialytic weight 
gains, albumin, hemoglobin and sodium measurements. The variables were statistically 
analyzed to reveal relationships, where and if available. The data collection tool was 
developed to obtain the necessary data from the patient’s record to meet the project’s 
objectives and complete statistical analysis to positively or negatively answer the 
research question.  The research question stated: Are HD patients who dialyze in a 
freestanding HD unit where BVM technology is available and used as an adjunctive tool 
along with assessment of clinical parameters more likely to be normotensive (BP < 
140/90 pre-dialysis. 130/80 post-dialysis) by attaining and maintaining a euvolemic state? 
Definition of Terms 
1. Antihypertensive medications: Medications prescribed by the patient’s provider(s) 
to control hypertension. Medications must be current and information will be 
collected on the data collection tool according to classification. Categories 
include: ACE-I, ARB, beta-blocker, calcium channel Blocker, central adrenergic 
blockers, alpha blockers, alpha-beta blockers, vasodilators, diuretics 
2. Clinical parameters: Assessment of weight, blood pressure, presence or absence 
of fluid deficit or excess before and after dialysis 
3. Co-morbidities: Any chronic illness that may affect the patient and their quality of 
life. This information taken from the 2728 form. 
4. Euvolemia The state of fluid equilibrium. The fluid state at which there are no 
signs of extracellular fluid deficit (hypovolemia) or extracellular fluid excess 
(hypervolemia).  
 10 
5. Hypertension (HTN) in hemodialysis (HD) patients: Pre-dialysis blood pressure 
(BP) greater than 140/90 mm/hg and post-dialysis BP greater than 130/80 mm/hg. 
6. Increased IDWG: Greater than 3000 ml gained in between prescribed dialysis 
sessions.  
7. Interdialytic weight gain (IDWG): Weight change calculated by subtracting post 
weight from pre-dialysis weight. Was measured in ml 
8. Prescribed treatment time: Time prescribed to be spent on dialysis, measured in 
minutes, prescribed by the provider to ensure dialysis adequacy and safe fluid 
removal. 
9. Primary cause of renal failure: The cause of decreased renal function necessitating 
the initiation of dialysis. This data will be taken from the 2728 form (see 
Appendix A), which is a standardized form every patient is required to have as 
part of his or her chart.  
10. Sodium profile: HD machine setting that allows for an increase amount of sodium 
to be delivered through the dialysate: 
 Hemoglobin 10-12 mg/dl  
 Serum albumin 3.5-5.0 
 Serum glucose 60-100 mg/dl 
 Serum sodium: 135-145 mEq/L.  
11. Ultrafiltration (UF) profile: HD machine setting that allows for fluid removal at 
different rates.  
The primary cause of end stage renal disease was obtained from the patient’s 
2728 form (see Appendix A). The Centers for Medicare and Medicaid Services (CMS) 
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requires the form for all newly diagnosed ESRD patients, regardless of their Medicare 
status or treatment modality. The 2728 form serves two purposes. The purposes are to 
provide medical evidence of an end-stage renal condition for Medicare entitlement, and 
to register the patient in a national renal registry. CMS provides the data to the USRDS 
for public reference and use in research. The patient’s co-morbidities was obtained from 
the 2728 and listed on the data collection tool (see Appendix B).  
Assumptions 
 There will be adequate patient population meeting inclusion criteria. 
 The recorded data will be accurate and reliable. 
 Correct analysis of data to answer the research question  
Importance of Proposed Project 
The proposed project will help fill gaps in nursing/medical knowledge regarding 
HTN and management of ECV in the hypertensive HD patient by promoting the need for 
ongoing ECV status and adjustment of DW. The obtained knowledge will contribute to 
nursing/medical knowledge by dispelling myths and supporting facts about that 
effectively managing the ECV status to improve control of HTN and may lead to the 
discontinuation of antihypertensive medication in some patients. The conducted research 
sought to lead to the implementation of best clinical practices in addition to KDOQI and 
KDIGO guidelines.  
Benefits of standardization would include an improvement in the clinical staff’s 
ability to assess a patient’s volemic state and improve the chances of achieving and 
maintaining the DW without experiences complications such as inter and intradialytic 
 12 
hypotension, cramps, nausea and/or vomiting, The study’s results may positively impact 
the practice of healthcare providers by assisting them to help meet the conditions of 
coverage (COC) as defined by CMS. The COC state “the principal goal of these 
conditions is to improve cardiovascular outcomes by optimizing fluid management 
practices and strategies during hemodialysis” (Hlebovy, 2008, p. 442). The conditions 
may be met by decreasing or preventing hospitalizations, decreasing morbidity and 
mortality rates associated with cardiac events by astute assessment and maintenance of 
the patient’s fluid status. Patient benefits include improved quality of life as evidenced by 
reduction in left ventricular mass that has been shown to decrease incidences of 
arrthymias and sudden cardiac death. The benefit of increased quality of life and patient 
longevity are priceless. 
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C H APT E R 2: L I T E R A T UR E R E V I E W  
Purpose 
The purpose of this literature review is to consider the discussions and data 
surrounding assessing extracellular volume (ECV) volume in hypertensive HD patients. 
The literature and guidelines reviewed indicate that HTN in the ESRD population is 
largely attributed to increase ECV and HTN, which remains uncontrolled despite accurate 
nursing assessment and provider intervention. The expected increase in the number of 
patients dependent on HD, along with economic impact of providing competent care, has 
increased the need to control HTN in this population. 
Background 
Investigators have concluded that cardiovascular disease (CVD) is the leading 
cause of morbidity and mortality in the ESRD population (Locatelli et al., 2004). The 
distinguishing CVD risk factors in the ESRD populations are: volume overload with 
consequent hypertension, anemia, deranged calcium-phosphorus metabolism, 
accumulation of specific uremic toxins, and chronic inflammatory processes (Locatelli et 
al, 2004). Unresolved hypertension contributes to the increased workload of the heart by 
affecting preload and afterload. Purcell, Manias, Williams, and Walker (2004) concluded 
hypertension particularly increases afterload.  
The main etiology of HTN in the ESRD population is ECV expansion (Purcell, 
Manias, Williams, and Walker, 2004). Guyton et al. established the significant role the 
kidneys play in the homeostasis of sodium and ECV (Purcell, Manias, Williams, and 
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Walker, 2004). An individual with normal kidney function balances salt and water intake 
through the gut and salt and water output through the kidneys that ultimately maintains 
the size of the ECV (Charra, 2007).  
As renal failure worsens the ability of the kidneys to excrete sodium decreases 
thereby leading to sodium excess that may abet HTN by expanding the ECV and 
increasing ventricular wall stress (cardiac output) during systolic ejection. This 
ventricular wall stress is known as afterload (Purcell, Manias, Williams, and Walker, 
2004) 
Afterload refers to factors that augment ventricular wall stress during systolic 
ejection (Purcell, Manias, Williams, and Walker, 2004). Sustained hypertension increases 
afterload and may result in left ventricular hypertrophy (LVH; 2004). LVH increases 
oxygen demands of the myocardium leading to increased risk of ischemic heart disease 
and possibly fatal arrhythmias. Foley et al. (1996) authenticated a lineal relationship 
between longstanding hypertension and the development of LVH. Horl and Horl (2002) 
established that LVH is a common characteristic of patients with kidney failure and 
significantly reduces their life expectancy. Foley (1996) documented that for every 
10mm/hg increase in mean arterial pressure (MAP) there was a 48% increased risk of 
LVH. The state of euvolemia is known as achieving a patient’s dry weight (DW). The 
definition of a patient’s dry weight was formulated based on multiple ideations but best 
stated by Charra (2007) as the lowest weight a patient can tolerate without intra and 
interdialytic symptoms such as hypotension and with no to minimal antihypertensive 
agents. Assessment of DW in HD patients relies heavily on clinical parameters (i.e. vital 
signs, patient comments, and physical exam). This imprecise method fails to take into 
 15 
account the dynamic nature of DW. DW may change during any period of illness, 
wellness, depression, gain and loss of lean body weight that may affect DW (Purcell, 
Manias, Williams, and Walker, 2004).  
The pillar of managing uncontrolled HTN in HD patients, after secondary causes 
have been eliminated, is achieving appropriate DW. Secondary causes of HTN in dialysis 
patients include activation of sympathetic nervous system, increased blood viscosity, 
stimulation of the Renin-Angiotensin system, and electrolyte shifts (Stankus, 2010). The 
problem of assessing dry weight on purely clinical grounds is rooted in the fact dry 
weight cannot be assessed by a single parameter (Purcell, Manias, Williams, and Walker, 
2004). Providers in the HD unit estimate DW. Factors such as the patient’s interdialytic 
well being, including appetite and energy level, should be incorporated and reassessed at 
least every 2 weeks to assure the patient’s post dialysis weight reflects an accurate DW 
(Purcell, Manias, Williams, and Walker, 2004).  
Hypertension is the leading and undisputed leading cause of CVD (Zoccali, 
Mallamaci, & Tripepi, 2002). In the ESRD population CVD mortality is the predominant 
cause of death. The USRDS annual report (NIDDKD, 2008) noted approximately 45% of 
overall mortality in ESRD patients receiving HD are attributed to cardiac events. The 
NKF-KDOQI guidelines state the HD prescription should be individualized to help the 
patient achieve euvolemic and normotensive states utilizing fluid control (2006). The 
need to provide clinicians with improved assessment skills in the field of ECV 
assessment is imperative to improve patient outcomes, patient quality of life, and 
decreased morbidity and mortality associated with uncontrolled HTN secondary to ECV 
excess. 
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Blood Pressure Guidelines in Hemodialysis Patients  
The NKF-KDQOI were first published in 2002, and revised in 2006, provide the 
framework for the treatment of uncontrolled hypertension in the ESRD patient. The NKF 
KDQOI guidelines are categorized into blood pressure management and management of 
hypertension (NKF-KDQOI, 2006). Blood pressure management in the ESRD patient is 
based on pre-dialysis blood pressure to guide antihypertensive therapy since blood 
pressure varies significantly upon the timing of the measurement.  
These guidelines state that it is difficult to relate usual BP readings to the ESRD 
patient because studies have shown both pre and post dialysis readings to measure 14 
points higher systolically and 5 points diastolically as compared to the non-ESRD patient 
(NKF-KDQOI, 2006). The guidelines also cite the availability of enough current data to 
define optimal blood pressure in ESRD patients so the committee selected 140/90 mm/hg 
as a pre-dialysis blood pressure target and 130/80 mm/hg as a post dialysis target.  
The guidelines clearly support the benefit of a lower target blood pressure but cite 
the increased morbidity and mortality of lower blood pressures in the ESRD population. 
This may be explained by reverse epidemiology according to Borsboom et al. (2006). 
The investigators found that long term uncontrolled hypertension coupled with increased 
ECV led to LVH, systolic, and diastolic dysfunction. The ESRD patient with severe 
cardiac failure presents as hypotensive in spite of their fluid status. The ESRD patient 
with this severe form of cardiac failure has a 1.5-3 times higher probability of death in 
the next 3-7 years as compared to the hypertensive ESRD patient (Borsboom et al, 2006). 
The NKF-KDQOI guidelines (2006) also cite dietary and nutritional management 
recommendations of HTN in the HD patient. The first recommendation states the 
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patient’s dietary sodium intake should be limited to 80 to 100 mEq/d. Tomson (2001) 
suggested that the nephrology community should concentrate on advising and helping 
dialysis patients to limit their salt intake which will help limit their thirst. Tomson 
continued by stating that patients drink for one of two reasons: thirst and because they 
feel like a drink (2001). Therefore, asking a patient to adhere to a fluid restriction without 
a sodium restriction is useless because if a patient’s sodium intake exceeds their output 
the stimulus to drink will be present due the body’s drive to maintain serum osmolarity 
(2001).  
In 2008 the Department of Health and Human Services, Centers for Medicare and 
Medicaid (CMS) published new guidelines for condition of coverage (COC) for 
establishing minimum health and safety standards for improving care and protecting 
Medicare and Medicaid beneficiaries (CMS, 2008). The conditions of coverage state “the 
adverse effects of ESRD, many patients experience labiality of blood pressure and fluid 
management, the management of which may require reassessment of medication needs, 
adjustments in target weight, and changes to the plan of care. The comprehensive 
assessment should include evaluation of the patient’s pre/intra/post and interdialytic 
blood pressures, interdialytic weight gains, target weight, and related intradialytic 
symptoms (e.g., hypertension, hypotension, muscular cramping) along with an analysis 
for potential root causes”. Both in and out patient dialysis facilities must meet the 
standards in order to be paid by CMS and since CMS is the major payer for those 
receiving HD. (CMS, 2008). Under the conditions of coverage an interdisciplinary team, 
consisting of the patient, registered nurse, physician, advanced practitioner, social 
worker, and dietician, are to convene to develop an appropriate plan of care.  
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Therefore, successful blood pressure and fluid management is mandated in order 
for dialysis units, physicians, and allied health professionals to be reimbursed (CMS, 
2008).  
Assessment of volume status in the HD patient involves the multi-disciplinary 
team approach of HD nurses, dieticians, patients and their caregivers. Although ECV 
assessment is not a precise science the perceptive HD nurse may employ various 
assessment methods including clinical parameters, physical exam, and in certain cases 
technology to assist in ECV management. 
Assessment of Volume Status  
Dry weight (DW), as it pertains to the ESRD population, is defined as the lowest 
weight a patient can tolerate without the development of symptoms (i.e. cramping) or 
hypotension in the absence of antihypertensive medications (Charra, 2007). In many 
dialysis units around the world DW is assessed by the presence or absence of symptoms 
such as dyspnea, headache, periorbital and pre-tibial edema, postural dizziness, cramps, 
hypotension and hypertension. Raimann, Lui, Ulloa, Kotanko, and Levin (2008) found 
that none of these symptoms were sufficiently specific or sensitive and exhibit a large 
inter and intra-individual variability. The earliest finding of fluid overload is jugular vein 
distention (JVD) and it is rarely assessed in dialysis units (Raimann, Lui, Ulloa, Kotanko, 
and Levin, 2008). 
Historically, assessment of volume status in the hypertensive HD patient has been 
elicited by measurement of clinical parameters and physical exam pre, intra, and post 
HD. Jaegar and Mehta (1999) found clinical assessment of ECV is crude and imprecise 
due to overestimation and underestimation of DW. Overestimation of DW leads to HTN, 
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cerebral vascular accidents (CVA), and congestive heart failure (CHF) that have been 
identified as the leading causes of death in the HD patient (Jaegar and Mehta, 1999). 
Underestimation of DW frequently leads to persistent hypotensive episodes, which may 
cause patient alienation from their HD caregivers by affecting delivery of dialysis 
through decreasing or missing HD sessions.  
Mitchell concluded (2002) pre-dialysis clinical assessment of ECV and DW is 
highly dependent on vital signs such as blood pressure, heart rate, temperature and in the 
case of HD patients their pre-dialysis weight. Pre-dialysis HTN may be secondary to 
excessive intra-dialytic weight gain (>3 kgs) (Reams and Elder, 2003). Reams and Elder 
also stressed the importance of assessing pre-dialysis HTN was not secondary to missed 
or held anti-hypertensive therapy. The importance of accurate pre-dialysis weight 
measurement should never be underestimated (Mitchell, 2002). Charra (2007) concluded, 
based on his clinical studies, that errors in weighing are frequent and may adversely 
impact the dialysis tolerance and the estimation of DW. Simple measures should be 
employed such as ensuring the scale is calibrated to zero pre and post treatment and 
educating the patient to wear similar clothing to every HD session to maintain pre-HD 
weight consistency.  
One of the most important pre-dialysis clinical assessment tools is determining 
the patient’s residual renal volume. The residual renal volume is the amount of 
interdialytic urine volume along with extrarenal water losses such as diarrhea, vomitus, 
and nasogastric secretions (Pace, 2007). Pace, concluded, a HD patient’s fluid allowance 
is 600 ml additional per 24 hours in addition to the patient’s urine output and extrarenal 
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water losses. Consistent assessment of a HD patient’s fluid allowance is paramount in 
preventing overestimation and underestimation of the patient’s volume status.  
Pre-dialytic and intra-dialytic volume assessment continues with physical exam 
and eliciting patient comments regarding interdialytic and intradialytic quality of life and 
general wellbeing (Mitchell, 2002). Purcell, Manias, Williams, and Walker (2004) found 
that the patient in the HD unit who attracts the most attention by experiencing 
hypotensive episodes, nausea and vomiting, or cramping during or after their dialysis 
treatment are more likely to report a perceived decrease in their quality of life. Intra-
dialytic patient complaints of fatigue, edema, or dyspnea that may lead to the inability of 
the patient to carry out activities of daily living are vital to astute volume assessment. The 
clinician should also refer to treatment history, preferably 2 weeks’ worth of treatment 
data, to assist in determination of volume status (Mitchell, 2002). 
The patient’s post dialysis weight coupled with the presence or absence of 
orthostatic hypotension may lead the HD nurse towards determining whether the DW is 
accurate or in need of adjustment. Charra (2007) found predialysis, interdialysis, and post 
dialysis assessment of edema often points to ECV excess but HD nurses must also assess 
the patient’s cardiac function and serum albumin.  
HD patients are often malnourished and a low albumin level leads to leakage of 
intravascular fluid into interstitial spaces, which leads to visible edema (Mitchell, 2002). 
Agarwal, Andersen, and Pratt (2008) undertook a study to answer the question “What is 
the role of pedal edema in the HD patient”? The cross-sectional study of asymptomatic 
HD patients’ deduced assessment of volume state is an important component of day-to-
day treatment of HD patients. The study concluded lower extremity edema correlates 
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with cardiovascular risk factors such as age, body mass index, and left ventricular mass 
but does not reflect volume in HD patients. Clinical parameters such as vital signs, 
patient’s complaints, and physical exam are critical components to assessment of ECV 
status but nursing knowledge is crucial in executing efficient and effective patient 
outcomes. Coupled with the need for keen nursing assessment is the advent of technology 
to assist with ECV management. 
Blood Volume Monitoring 
Assessment of ECV in HD has long depended on edema, presence or absence of 
dyspnea, HTN, fatigue and patient complaints. This imprecise method fails to take into 
account the dynamic nature of DW in which any period of illness, depression, gain or 
loss of lean body weight may affect ECV (Purcell, Manias, Williams, and Walker 2004). 
Of all the advancements in dialysis therapy the use of the blood volume monitor (BVM) 
has proven to be the most useful tool in DW attainment with little risk of hypotensive 
episodes in the ESRD patient (Heerspink et al., 2009). BVM is a non-invasive method, 
which monitors the fluid available in the intravascular space against the rate of fluid 
removal during dialysis.  
This is accomplished by measuring plasma refill during the hemodialysis process. 
Plasma refill is the shift of poisons and fluids from the intracellular space to the 
extracellular space into the intravascular space/circulating blood volume. During the 
dialysis session, excess fluids and toxins are removed from the circulating blood volume 
and if there is excess fluid or toxins in either the intracellular or extracellular 
compartments it is shifted to the intravascular space. This process is known as plasma 
refill (Heerspink et al, 2009).  
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The BVM utilizes the patient’s hematocrit (HCT) increased or decreased ECV has 
a direct inverse relationship with a increase or decrease blood volume measured through 
real time HCT (Leypoldt et al., 2002). Steuer, Germain, Leypoldt, and Cheung (1998) 
concluded that the use of BVM during HD facilitated the identification of patients with 
increased ECV while permitting greater removal of excess body fluids without a 
substantial increase symptom during treatment.  
BVM allows the HD nurse to utilize clinical parameters and physical exam to 
predict and avoid interdialytic morbidity such as hypotensive episodes. Charra (2007) 
concluded BVM in conjunction with discerning nursing judgment might result in 
decreased patient morbidity and mortality. BVM is particularly useful when assessing 
ECV status in hypertensive elder patients that have decreased body water related to 
increased body fat, decreased muscle mass and decreased ability to regulate water and 
sodium balance (McCance & Huether, 1998).  
The advantages of the BVM are that HD nurses and staff are able to make 
immediate changes to the rate and volume of fluid removal before an adverse patient 
event. The disadvantages of BVM use are lack of access to the majority of HD patients 
secondary to economic factors and accurate interpretation of the data by nursing staff. 
Purcell, Manias, Williams, and Walker (2004) looked at whether clinical parameters and 
physical exam used alone or in conjunction with BVM yielded improved outcomes. They 
found the most important component is seasoned nursing judgment. 
The autonomy of the dialysis nurse is well known within the health care 
community. Dialysis nurses autonomy may be secondary to the highly technical nature of 
their practice and the need to make immediate decisions regarding the patient’s treatment 
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often without the presence of a physician or advanced practitioner. Bonner and Walker 
(2004) examined nephrology nurses and their role in the blurring of boundaries as it 
relates to patient care. The study’s participants included 6 novice nephrology nurses and 
11 expert nephrology nurses.  This study utilized a grounded theory methodology and 
symbolic interaction. Nephrology nurses, in particular HD nurses, are known for their 
autonomy.  
Nurses’ autonomy in dialysis units stem from the highly specified nursing tasks 
that untrained and novice nurses, physicians and ancillary staff are unable to perform. In 
order for a nurse to be considered safe and competent, an average of at least 12-18 
months training is needed (Bonner and Walker, 2004). Expert nephrology nurses were 
defined as nurses with more than 5 years hemodialysis experience and novice nurses 
were defined as nurses with less than 5 years experience. Although Nephrologists and 
advanced practice practitioners are competent in managing HD patients, many lack the 
knowledge and technical ability to perform the actual treatment and its associated 
functions. 
The study found that only the expert nephrology nurses were more likely to make 
patient care decisions that would normally involve a provider’s order and did so by 
moving intermittently and purposefully for the benefit of particular patients. Expert 
nurses, in this study, altered medications that were used to treat symptoms of renal failure 
such as electrolyte imbalances, anemia, and hypertension. The nurse’s actions consisted 
mainly of reducing or stopping a drug and adjusting fluid removal during HD. The study 
highlighted the fact that nephrology nurses tend to act in the immediate interest of patient 
by stabilizing a potentially dangerous situation. Educating the staff regarding what 
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benefits the patient in the long run will influence current treatment decisions and 
outcomes (Bonner and Walker, 2004) by setting protocols that will allow all nurses to 
practice within their scope. 
Summary 
The goal of this literature review was to assess the current literature and 
guidelines as related to assessment of ECV status in uncontrolled HTN in HD patients. 
The purpose of this literature review is to support the assessment of ECV status through 
clinical parameters and physical assessment and where available BVM. The findings of a 
project directed at determining whether there is improved patient outcomes when clinical 
parameters and physical exam is used compared to clinical parameters, physical exam, 
and BVM may lead to the purchase and use of the BVM in settings where it is currently 
not available. 
The NKF-KDOQI guidelines state the HD prescription should be individualized 
to help the patient achieve euvolemic and normotensive states utilizing fluid and sodium 
control (National Kidney Foundation’s Executive Summary, 2006). The need to provide 
clinicians with improved assessment skills and protocols in the area of ECV assessment 
are imperative to improve patient outcomes, and decrease morbidity and mortality 
associated with CVD. DW assessment and determination is well within the scope of 
practice of HD nurses. Attempts to improve ECV volume status assessment will increase 
patient’s quality of life as well as decreasing costs associated with medications and 
hospitalizations.  
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C H APT E R 3: M E T H O D O L O G Y 
A retrospective, descriptive, cross-sectional design was employed in the chart 
review process. The identified population consisted of patients of a freestanding 
hemodialysis unit in the Southern-Eastern United States with the diagnosis of ESRD and 
HTN with secondary causes of HTN excluded. A data collection instrument was used to 
obtain needed data.  The descriptive design was chosen because it allowed the researcher 
to observe, chronicle, archive facets of HTN and ECV assessment and management in the 
HD patient. The patient records were available to the researcher during the operating 
hours of a facility that employs BVM as a fluid management tool.  
The makers of the BVM, HemaMetric, state the monitor is a continuous quality 
improvement management tool that allows clinicians to safely and consistently dialyze 
patients to their ideal DW, resulting in improved measurable patient outcomes such as 
decreased fluid related hospitalizations, decreased pre-dialysis HTN, and decreased 
number of antihypertensive medications.  
The use of descriptive research in this study provided insight into the validity of 
the BVM maker’s claims as well as making observations based on trends among the 
hypertensive HD patients whose records were reviewed. Descriptive research allows the 
researcher to explore exposed relationships among the variables even in the presence of 
large amounts of collected data. An identified advantage of appropriating descriptive 
research is that the what, when, where, and why of the research question is answered. 
Disadvantages of the descriptive research method are that the information gathered may 
be ubiquitous and risk for potential research bias is possible.  
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Sampling 
The size of the study’s sample was determined by a power analysis. The analysis 
determined the review of 50 charts should yield enough data to answer the research 
question. However, there were only 42 client records that met inclusion criteria. Not 
having enough patients from which to collect data as recommended by the power analysis 
was identified as limitation. The 42 charts that did meet the inclusion criteria were used 
for data extrapolation and analysis. 
Project Design 
Demographic variables (age, gender, and race) were collected from the facility’s 
electronic records. Descriptive variables such as the patient’s primary cause of ESRD and 
co-morbidities were obtained from the patient’s 2728 form in addition to recent hospital 
and provider documentation. Other descriptive variables such as dates of BVM use, 
prescribed anti-hypertensive medications, blood pressures, pre and post dialysis weights, 
albumin, hemoglobin, and sodium levels were obtained from electronic records including 
the facility laboratory’s website. Data on these variables measured before and after BVM 
intervention was collected.  
The identified variables were selected because they were expected to reveal 
relationships that may assist in assessment and management of ECV status in the 
hypertensive HD patient. The operational definition of HTN in HD patients was based on 
the NKF-KDOQI guidelines (2006) of pre-dialysis BP readings of 140/90 mm/hg and 
greater and post-dialysis readings of 130/80 mm/hg and greater.  
The data collection tool summarized information pertaining to the demographic 
and descriptive variables listed above. The collected data was evaluated at nominal and 
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ratio levels. Nominal levels were used in the measurement of primary and co-morbid 
diagnosis, anti-hypertensive medications, and demographic variables. Ratio levels were 
used in reporting age, intradialytic weights, blood pressures, albumin, hemoglobin, and 
sodium levels. 
Subjects/Setting 
The data was collected from the records of patients receiving treatment in the 
hemodialysis unit. The data gathering and reviewing process took place during the 
facility’s operating hours. Patient charts and documents were not removed from the 
facility. A report was created to include variables needed for data analysis and was used 
to populate the data collection tool. The inclusion criteria for the study’s subjects 
included:  
1. ESRD patients with at least 6 months of hemodialysis treatment history 
2. History of hemodialysis at the current outpatient hemodialysis unit for 3 months 
3. May be on the kidney transplant list 
4. Documented diagnosis of hypertension on admission to dialysis unit or recent 
diagnosis within the prior 6 months 
5. History of antihypertensive therapy (current or discontinued) within the prior 3 
months 
6. Permanent patient of medical director or physicians who round on monthly basis. 
Exclusion criteria included: 
1. ESRD patient less than 18 years of age 
2. Less than 3 months on hemodialysis 
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3. No admitting diagnosis of hypertension or recent diagnosis within 6 months prior 
to study initiation 
4. Individuals prescribed anti-hypertensive therapy for secondary causes such as rate 
control  
Human Subjects 
Because this project was a chart review, no tests, procedures, or direct patient 
contact was conducted, so there was no potential for harm to human subjects. The 
university’s internal review board granted permission (IRB; see Appendix C) to proceed 
with the study after review of the study, methods employed and procedures to protect the 
patient and their information. .  
Inst ruments 
The purpose of the data collection tool (see Appendix B) was to analyze patient 
data before and after the use of BVM in order to answer the research question, which 
stated that the use of BVM along with the assessment of clinical parameters decreases 
blood pressure by normalizing the ECV. The tool used codes to allow for statistical 
analysis of data extracted and was piloted with sample of data of the studied variables. 
An identification number, instead of the patient’s name or other identifying data, was 
assigned to the patient and the list kept only by the researcher in a secure location. . If 
confidentiality was breeched, a plan was in place to stop the breech, if possible, and 
notify the facility’s management, patients, and other vested personnel. The Health 
Insurance Portability and Accountability Act (HIPPA) provides for the privacy of 
 29 
personal health information. HIPPA criteria will be maintained via the study’s 
confidentiality protocol as mentioned above.  
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C H APT E R 4: R ESU L TS 
The purpose of this chapter is to present the findings of the Comparative Analysis 
of Assessment of Excess Extracellular Volume in Hypertensive Hemodialysis Patients. 
This comparative retrospective analysis is based on data from 42 patient files meeting the 
inclusion and exclusion criteria outlined in Chapter 3. 
Sample 
Figure 1 illustrates the gender distribution of the sample of this study. Of the 42 
participants, 60% were male and 40% were female. Figure 2 illustrates the national 
average gender distribution in dialysis patients per the USRDS annual report (NIDDKD, 
2008). This sample had more females than the reported national average. The mean age 
of the participant was 58.6 years with a standard deviation of 16. Figure 3 illustrates the 
sample by race. Of the 42 participants, 45% were Caucasian, 43% were 
Hispanics/Latinos, 7% were of African descent, and 5% were Asian. Figure 4 illustrates 
race of dialysis patients by national average.  
Primary Cause of End Stage Renal Disease 
Table 1 describes the primary cause of end stage renal disease (ESRD) for the 
sample (N = 42). This data was obtained from the patient’s End Stage Renal Disease 
Medical Evidence Report (2728 form). Diabetes Mellitus was listed as the primary cause 
of ESRD in 48% of the participants followed by hypertension/large vessel disease in 33% 
of the participants. The sample had a higher incidence of hypertension compared to the  
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Figure 1. Gender of dialysis patients (study participants). 
 
Note. (N = 382,334). 
Figure 2. Gender of dialysis patients (national average).  
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40%
Gender
Male (N=25)
Female (N=17)
55%
45%
Gender
Male (N=210,569)
Female (N=171,765)
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Figure 3. Race of dialysis patients (study participants).
 
National Institute of Diabetes and Digestive and Kidney Diseases. (2010). United States 
Renal Data System. 2010 Annual Report. Atlas of Chronic Kidney Disease and End 
Stage Renal Disease in the United States. Retrieved from http://www.usrds .org/atlas.htm 
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Figure 4. Race of dialysis patients (national data). 
National average (thirty-three percent  compared to twenty-eight percent). 
Glomerulonephritis was listed as the primary cause in 7% of the participants and 
interstitial nephritis/ pyelonephritis and neoplasms/tumors were each the cause of ESRD 
in 5% of participants. Secondary Glomerulonephritis was responsible for 2% of ESRD in 
study participants. Table 2 describes the primary cause of ESRD per data obtained from 
the USRDS (NIDDKD, 2008). 
 
Table 1. Primary Cause of End Stage Renal Disease 
Primary Cause of End Stage Renal Disease (Study Participants) 
Primary Cause N % 
Diabetes Mellitus 20 47.6 
Hypertension/Large Vessel Disease 14 33 
Glomerulonephritis 3 7.1 
Interstitial Nephritis/Pyelonephritis 2 4.8 
Neoplasm/Tumors 2 4.8 
Secondary Glomerulonephritis 1 2.4 
 
 
 
Table 2. Primary Cause of End Stage Renal Disease (national data) 
Primary Cause of End Stage Renal Disease (national data) 
Primary Cause N % 
Diabetes Mellitus 167,292 42.8 
Glomerulonephritis/ Secondary Glomerulonephritis 39,693 10.8 
Hypertension/Large Vessel Disease 107,670 28.2 
Other Known 35,015 9.2 
Unknown  13,676 3.6 
Interstitial Nephritis/Pyelonephritis 7,329 1.9 
Missing Cause 1,352 0.4 
Neoplasms/Tumors NA NA 
Note. N = 382344. 
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Co-Morbidities 
Table 3 depicts the co-morbidities of the participants in the study (N = 42) 
obtained from the End Stage Renal Disease Medical Evidence Report. Co-morbidities are 
diseases or disorders that coexist with a primary disease but also stand alone as a specific 
disease. Diabetes Mellitus was the most frequent co-morbidity and was present in 48% of 
the participants. Cardiovascular disease was present in 45% of the participants. Twenty-
one percent had chronic obstructive pulmonary disease and. nineteen percent of 
participants had peripheral vascular disease. Amputations were documented in 17% of 
the participants, Cerebral vascular disease was reported in 10% of the sample. 
Malignancy/neoplasm and tobacco abuse were each diagnosed in 5% of the participants 
and 2% had documentation of hepatic disease.  
 
Table 3. Co-Morbidities of Study Participants 
Co-Morbidities of Study Participants 
Co-Morbidities N % 
Diabetes Mellitus 20 48 
Cardiovascular Disease 19 45 
Cerebral Vascular Accident 4 10 
Chronic Obstructive Pulmonary Disease 9 21 
Peripheral Vascular Disease 8 19 
Amputation 7 17 
Malignancy/Neoplasm 2 5 
Tobacco Abuse 2 5 
Hepatic Disease 1 2 
 
Antihypertensive Medications 
Table 4 lists the different classes of antihypertensive medication prescribed to the 
participants. Fifty-four percent of the participants were prescribed beta-blockers and 37% 
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received Dihydropyridine calcium channel blockers. Angiotensin converting enzyme 
inhibitors were prescribed for 31%, of the participants. 24% received central agonists. 
Twelve percent of participants took both angiotensin receptor blockers and diuretics. 
Benzothiazepine calcium channel blockers were taken by 2% of the participants. 
 
Table 4. Participants’ Antihypertensive Medications 
Participant’s Antihypertensive Medications 
Antihypertensive Class N % 
Angiotensin Converting Enzyme-Inhibitors 13 31 
Angiotensin Receptor Blockers 5 12 
Beta Blockers 22 52 
Calcium Channel Blockers (Benzothiazepines) 1 2 
Calcium Channel Blockers (Dihydropyridines) 15 36 
Central Agonists 10 24 
Diuretics 5 12 
 
 
Research Question 
Analysis of this data was done to accept or reject the question “Are HD patients 
who dialyze in a freestanding HD unit where BVM technology is used as an adjunctive 
tool along with assessment of clinical parameters more likely to be normotensive (BP < 
140/90 pre-dialysis. 130/80 post-dialysis) secondary to achieving and maintaining an 
adequate dry weight?” In order to answer this question, statistical analyses were run using 
SPSS statistical software. Descriptive statistics were run to obtain the minimum, 
maximum, and mean of each variable and then paired samples test was completed on 
paired variables. If the p value is less than or equal the mean correlation coefficient (p 
value less than or equal to .05), the question was answered as yes. If the p value is 
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greater than the mean correlation coefficient (p value greater than .05), the question was 
answered as no.  
To further explore the effect of the use of BVM on this client group, other 
physiologic variables that are known to impact blood pressure were also examined. Thus, 
tin addition to examination of  pre and post BVM pre-dialysis systolic blood pressure, 
pre-dialysis diastolic blood pressure, post-dialysis systolic blood pressure and post-
dialysis diastolic blood pressure, serum albumin, hemoglobin, and serum sodium were 
also examined to evaluate if their reported values were be closer to or at the nationally set 
goals with the use of the BVM to aid in the assistance of proper dry weight assessment 
and attainment.  
The paired sample t-test is a statistical test which tests the means of two samples 
that are correlated. Paired sample t-test is used in before after studies, or when the 
samples are the matched pairs. Pair samples statistics was run to assess variables pre and 
post BVM use. Table 5 illustrates the variable, the mean, the matched pair’s mean and the 
significance value. 
 
Table 5. Descriptive Statistics for Pre- and Post-BVM Use 
Descriptive Statistics for Pre- and Post-BVM Use 
Pre BVM Mean Post BVM Mean Matched 
Pair’s Mean 
Sig. 
(2-tailed) 
Pre-dialysis 
systolic blood 
pressure 
159.83 Pre-dialysis 
systolic blood 
pressure 
149.19 10.64 .000 
Pre-dialysis 
diastolic blood 
pressure 
78.6 Pre-dialysis 
diastolic blood 
pressure 
74.74 3.87 .055 
Post-dialysis 
systolic blood 
pressure 
130.21 Post-dialysis 
systolic blood 
pressure 
129.07 1.14 .692 
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Post dialysis 
diastolic blood 
pressure 
65.71 Post dialysis 
diastolic blood 
pressure 
65.5 .214 .899 
Interdialytic 
weight gain 
3.3 Interdialytic 
weight gain 
3.2 .035 .586 
Serum 
Albumin 
3.698 Serum 
Albumin 
3.705 -.007 .637 
Hemoglobin 12 Hemoglobin 11.98 .057 .641 
Serum Sodium 138.14 Serum Sodium 137.67 .476 .023 
Figure 5 illustrates pre-treatment systolic blood pressure, pre and post BVM. The 
significance value (p-value) was found to be .000. A paired samples t test revealed a 
statistically reliable difference between the mean number pre BVM pre treatment systolic 
blood pressure and the post BVM pre treatment systolic blood pressure. Figure 6 
illustrates pre-treatment diastolic blood pressure, pre and post BVM. The significance 
value (p-value) was found to be .055. A paired samples t test failed to reveal a 
statistically reliable difference between the mean number pre BVM pre treatment 
diastolic blood pressure and the post BVM pre treatment diastolic blood pressure. Figure 
7 illustrates post-treatment systolic blood pressure, pre and post BVM. The significance 
value (p-value) was found to be .692. A paired samples t test failed to reveal a 
statistically significant difference between the mean number pre BVM post treatment 
systolic blood pressure and the post BVM pre treatment systolic blood pressure.  
Figure 8 illustrates post-treatment diastolic blood pressure, pre and post BVM. 
The significance value (p-value) was found to be .899. A paired samples t test failed to 
reveal a statistically reliable difference between the mean number pre BVM post 
treatment diastolic blood pressure and the post BVM post treatment diastolic blood 
pressure.  
Figure 9 illustrates post-treatment systolic blood pressure, pre and post BVM. The 
significance value was found to be .899. A paired samples t test failed to reveal a 
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statistically reliable difference between the mean number pre BVM post treatment 
diastolic blood pressure and the post BVM post treatment diastolic blood pressure.. 
Figure 10 illustrates interdialytic weight gain pre and post BVM. The significance value 
was found to be .586. A paired samples t test failed to reveal a statistically reliable 
difference between the mean numbers pre and post BVM interdialytic weight gain.  
Figure 11 illustrates serum Albumin pre and post BVM. The significance value 
(p-value) was found to be .637. A paired samples t test failed to reveal a statistically 
reliable difference between the mean numbers pre and post BVM serum Albumin. Figure 
12 illustrates the Hemoglobin pre and post BVM. The significance value was found to be 
.641. A paired samples t test failed to reveal a statistically reliable difference between the 
mean numbers pre and post BVM hemoglobin. Figure 13 illustrates serum Sodium, pre 
and post BVM. The significance value was found to be .023. A paired samples t test 
revealed a statistically reliable difference between the mean number pre and post BVM 
serum sodium levels. 
 
 39 
 
Figure 5. Pre-treatment systolic blood pressure: pre- and post-BVM. 
 
 
Figure 6. Diastolic blood pressure pre- and post-BVM 
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Figure 7. Post-treatment systolic blood pressure. 
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Figure 8. Post­treatment systolic blood pressure: Pre­ and post­BVM.
 
Figure 9. Post-treatment diastolic blood pressure: Pre- and post-BVM. 
 
 
 
 
Figure 10. Interdialytic weight gain: Pre­ and post­BVM. 
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Figure 11. Serum albumin: Pre­ and post­BVM.  
 
 
 
Figure 12. Hemoglobin: Pre- and post-BVM.  
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Figure 13. Serum sodium: Pre- and post-BVM.  
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C H APT E R 5: D ISC USSI O N 
The purpose of this comparative retrospective chart review was to assess the 
possible correlation between control of hypertension in hemodialysis patients when fluid 
management technology is used in conjunction with the assessment of clinical parameters 
to manage DW. The effective management of hypertension in this population is highly 
dependent on optimal fluid removal in manner that does not illicit intra, inter or post 
dialytic complications such as nausea, vomiting, cramps in extremities, and fluid 
resuscitation to treat hypotension (San Miguel, 2010). The problem of how best to assess 
fluid status in ESRD patients has long plagued hemodialysis healthcare providers charged 
with maintaining the balance among hypovolemia, euvolemia, and hypervolemia. 
Hemodialysis nurses are responsible for carrying out the nephrologist and advanced 
practitioner’s prescription for the dialysis treatment including the prescribed dry weight. 
This is especially true for nephrology nurses since they are involved in the patient’s 
treatment and may contribute either positively or negatively to the patient’s outcome. 
Achieving optimal dry weight (DW) is often difficult in the outpatient 
hemodialysis unit because of the lack of credible criteria to determine if the DW has been 
achieved or whether a particular assessment is superior to another in assessing DW. A 
prospective study of 150 HD patients found reduction in the DW has a positive effect on 
blood pressure but had a negative impact on intravascular volume depletion to the point 
of necessitating fluid resuscitation and clotting of the vascular access (Agarwal et al., 
2009).  
Another variable that further confounds the management of DW is the patient. 
HD patients are aware of the need to restrict their fluid intake, particularly those with 
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little to none residual renal function. San Miguel (2010) stated that the sensation of thirst 
is often results in behavioral activities such as drinking whereas the onset of drinking 
results from motivational and cognitive processed that elicit the behavior. Fisher (2004) 
observed that fluid restriction among HD patients creates an uncomfortable state of 
ambivalence regarding drinking and Fisher conceptualized a model regarding fluid intake 
in this population. The conceptualized model assumes there is tension between the need 
to restrict fluid intake and the desire to drink and it is this focus on fluid restriction and an 
increased sensation of thirst (Fisher, 2004). The accumulation of these sensations triggers 
a sense of powerlessness and poor self-efficacy.  
The direct relation between increased extracellular volume and hypertension led 
to the formulation of the research question. The question stated: “Do hypertensive 
patients who dialyze in dialysis unit where BVM technology is used along with the 
assessment of clinical parameters more likely to be normotensive as defined by a pre 
dialysis blood pressure of less than 140/90 and post dialysis blood pressure less than 
130/80”? The following sections describe the study’s findings, limitations, conclusions, 
implications to nursing, future research recommendations, and summary. 
The data collection tool was tested and retested for usability through a pilot study. 
The findings from the pilot study were then applied to the tool and another pilot study 
was completed. At the conclusion of the pilot study, the tool was found to usable to 
extrapolate data needed for analysis.  
Demographics 
The retrospective chart review was completed on 42 charts that met the inclusion 
criteria. The demographics of the sample were representative of dialysis units in the 
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United States and the sample was compared to the most recently retrieved data from the 
United States Renal Data Systems (2010). Of the 42-hemodialysis patients 40.5% were 
female and 59.5% compared to the national average of 44% females and 56% males.  
The four races identified in the sample included: African descent, (includes 
African Americans and Afro- Caribbean), Caucasian, Hispanic/Latino, and Asian. The 
sample yielded 7.1% of African descent compared to the national average of 37.1%. 
Caucasians comprised 45.2% compared to the national average of 55.8%. 
Hispanic/Latinos made up 42.9% of the sample compared to the national average of 16%. 
Lastly, 4.8% of the sample was Asian, which matched the national average. The sample 
yielded a large percentage of Hispanic/Latino patients compared to the national average 
(42.9% vs.16%) and conversely small percentage of African descent compared also to the 
national average (7.1% vs.37.1%).  
The data was obtained from a geographic location where the population was 
59.5% Caucasian, 16.1% African descent, 21.5% Hispanic/Latino and with an Asian 
population of less than 1%. The disproportionate percentage of African descent and 
Hispanic/Latinos within the sample is seen as a factor which may have affected the 
outcome of the study’s results especially in regards to the higher than national average of 
diabetes mellitus seen in the Hispanic population. 
Primary Cause of End Stage Renal Disease 
The primary causes of end stage renal disease (ESRD) identified in the records of 
patient reviewed for this study were diabetes mellitus, Glomerulonephritis, secondary 
glomerulonephritis, interstitial nephritis/pyelonephritis, hypertension/large vessel disease, 
and neoplasm/tumors. Diabetes mellitus was the primary cause of ESRD in 47.6% of the 
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sample compared to the national average of 43.8%. Hypertension/large vessel disease 
was listed as the primary cause of ESRD in 33% of the sample compared to the national 
average of 28.3%. Glomerulonephritis was listed in 7.1% compared to the national 
average of 10.4%. 2.4% of the sample listed Secondary Glomerulonephritis listed as the 
primary cause of ESRD that was equal to the national average. Interstitial 
nephritis/pyelonephritis was responsible for 4.8% of the cases as the primary cause of 
ESRD in the sample compared to the national average of 3.2%. Lastly neoplasms/Tumors 
were responsible for 4.8% of the causes compared to 2.4% national average. Diabetes 
mellitus and hypertension/large vessel diseases were noted to be more prevalent in the 
studied population, which may be secondary to the large Hispanic/Latino population in 
the sample.  
Co-Morbidities 
Co-morbidities identified in this study included amputation, chronic obstructive 
pulmonary disease (COPD), cerebral vascular accident (CVA), cardiovascular disease 
(CVD), diabetes mellitus (DM), malignancy/neoplasm, hepatic disease, depression and 
tobacco abuse. The co-morbidities were taken from the list provided on the 2728 form. 
COPD, CVD, DM, and PVD had the highest occurrences of co-morbidities within the 
study sample. Hypertension was not counted in co-morbidities, as it was an inclusion 
criterion for the study. 
Antihypertensive Medication 
The data revealed that 31% of the sample were prescribed ACE-I, 11.9% were 
prescribed ARB. Calcium channel blockers (CCB) (all classes) are the most widely 
 48 
prescribed class of drugs for dialysis patients (NKF Clinical Practice Guidelines, 2006). 
38.1% of the patients were prescribed CCB. CCB appears to be more effective when the 
plasma volume is expanded and since hypertension in this population is a result of 
extracellular volume expansion this class of medications has an advantage of reducing 
hypertension hemodialysis patients. 
B lood Pressure M anagement 
The comparative analysis of excess extracellular volume in hypertensive 
hemodialysis (HD) patients sought to answer the question which asked “Are hypertensive 
hemodialysis patients who dialyze in a freestanding dialysis unit, with blood volume 
monitoring (BVM) technology available, more likely to be normotensive or closer to 
normotension as defined by a pre dialysis blood pressure of less than 140/90 and post 
dialysis blood pressure less than 130/80”? The paired samples T-test was run on the 
collected data to assess the changes or lack thereof, to correctly answer the research 
question within the paired data.  
The four paired samples included: Pre-BVM: pre-dialysis SBP compared to post-
BVM: SBP, Pre-BVM: Pre-dialysis DBP compared to post-BVM: Pre-BVM post-
dialysis SBP to post-BVM: post-dialysis SBP, and Pre-BVM: post-dialysis DBP. The 
records reviewed in this retrospective chart review demonstrated that the pre BVM pre 
dialysis systolic blood pressure (SBP) had a mean of 160 mm/hg compared to a post 
BVM pre dialysis SBP of 149 mm/hg. This result was found to be statistically significant 
with a significance value (2-tailed) of .000 (p≤0.05) so the answer to the research 
question “Are hypertensive hemodialysis patients who dialyze in a freestanding dialysis 
unit, with BVM) technology available and utilized, more likely to be normotensive as 
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defined by a pre dialysis blood pressure of less than 140/90 and post dialysis blood 
pressure less than 130/80?” is yes in relation to pre dialysis systolic blood pressure.  
This statistically significant finding supports the correlation between reduction in 
the HD patient’s extracellular volume and improved blood pressure control. The 
reduction of pre-dialysis SBP was significant because Agarwal (2006) made the 
observation that most patients on hemodialysis have systolic hypertension that may or 
may not coexist with diastolic hypertension. Pre dialysis systolic blood pressure is 
superior to post dialysis blood pressure as a screening tool for detecting hypertension in 
dialysis patients (Charra, 2007).  
The pre BVM post dialysis SBP mean was 130 mm/hg and the post BVM post 
dialysis mean was 129 mm/hg. There was no statistical significance noted (.692). The 
answer to the research question “Are hypertensive hemodialysis patients who dialyze in a 
freestanding dialysis unit, with BVM) technology available and used, more likely to be 
normotensive as defined by a pre dialysis blood pressure of less than 140/90 and post 
dialysis blood pressure less than 130/80?” is no in relation to systolic blood pressure 
before and after BVM use. 
 However, it is important to note that both values met guidelines of a post dialysis 
SBP of less than or equal to 130 mm/hg. This finding leads one to speculate that the 
availability and use of the BVM technology may be a reason why this goal is attained.  
The pre BVM pre dialysis diastolic blood pressure was found to have a mean of 
79 mm/hg compared to the post BVM pre dialysis DBP mean of 75 mm/hg. Again, this 
value was not statically significant (.055). The answer to the research question “Are 
hypertensive hemodialysis patients who dialyze in a freestanding dialysis unit, with 
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BVM) technology available and used, more likely to be normotensive as defined by a pre 
dialysis blood pressure of less than 140/90 and post dialysis blood pressure less than 
130/80?” is, again, no in relation diastolic blood pressure before and after BVM use.  
However, again, this may have clinical significance because national 
guidelines/recommendations were met for systolic and diastolic readings.  
The pre BVM post dialysis DBP presented with a mean of 67 mm/hg compared to 
post BVM post dialysis DBP of 66 mm/hg that is once again not statistically significant 
(.899). The answer to the research question “Are hypertensive hemodialysis patients who 
dialyze in a freestanding dialysis unit, with BVM) technology available and used, more 
likely to be normotensive as defined by a pre dialysis blood pressure of less than 140/90 
and post dialysis blood pressure less than 130/80?” is no in relation to pre and post 
dialysis diastolic blood pressure. However, it is important to note that the diastolic values 
at both points met guidelines and it is important to remember many patients have systolic 
hypertension without diastolic hypertension. 
Other Observations 
While not related to the specific research question, the following summarizes 
observations based on data collected in association with this study. 
Interdialytic Weight Gain 
The mean pre BVM interdialytic weight gain (IDWG) average was 3.3kg 
compared to the mean of 3.3kg post BVM intervention. The findings were not statically 
significant (p≤0.05). NKF-KDOQI (2006) state the average IDWG should be less than or 
equal to 3kg. Kalantar-Zadeh et al. (2009) found in long-term hemodialysis patients, a 
higher IDWG is associated with poor survival and increased cardiovascular death. Most 
 51 
importantly they found the patients with the lowest interdialytic fluid retention had the 
greatest risk of survival observed across the subgroups of hemodialysis patients.  
Can the use of the BVM technology used in conjunction with the assessment of 
clinical parameters help patients control their intradialytic weight gain? When a patient is 
eulvolemic there may be an increase in energy that leads to an overall sense of wellbeing, 
which may mitigate improved adherence with dietary fluid restriction. The BVM may be 
effective in attaining the correct dry weight by showing a visualization of the patient’s 
current fluid status and allowing active patient participation in their care. Lindberg (2008) 
made the observation that pragmatic and effective ways of helping patients with fluid 
management are lacking and the results o of intervention studies in this area have in 
general been disappointing. Baraz (2010) conducted a randomized clinical trial that 
provided educational video two times a week for two weeks. The video emphasized 
ESRD dietary management, identification of appropriate provisions, fluid restrictions, 
and consequences of fluid overload. The outcome was fluid overload was reduced. This 
study validated the importance of education and patient involvement to impact outcomes. 
Albumin  
The pre BVM mean for serum Albumin was 3.7 g/dl and the post BVM serum 
Albumin mean was also 3.7. This finding was not statistically significant because of a p 
value ≥ 0.5 (p = .637). San Miguel (2010) stated that assessment of Albumin is pivotal, in 
combination of other clinical parameters, when assessing dry weight (DW). Particular 
attention should be paid to patients with a low Albumin (<3.4 g/dl) because these patients 
are likely to show signs of not tolerating fluid removal with HD such as hypotension and 
cramps despite the presence of excess extracellular volume (2010).  
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Sodium 
The pre BVM mean for sodium was 138 and the post BVM mean was 137. The 
finding was found to be statistically significant with a p value of .023. With the removal 
of ECV to achieve the prescribed dry weight there is a decrease in the serum sodium as 
the ECV normalizes (2007). Sodium is often the forgotten element in managing a 
patient’s ECV and dry weight but assessment to serum sodium levels may assist in ECV 
and dry weight management by monitoring fluctuations in reported values. During the 
dialysis process often the sodium is increased to alleviate intradialytic symptoms such as 
hypotension and cramping. The hemodialysis machine has the ability to deliver between 
135-145mEq/L of sodium during a dialysis treatment (2007).  
Agarwal (2006) used the example of a patient who weighs 72kg. The total body 
water is estimated at 43L. If the pre dialysis sodium concentration is 135mEq/L and the 
patient is dialyzed against 145mEq/L, a total of 430mEq of sodium will be delivered to 
the patient during the treatment during a typical of 210-240 minutes. This is equal to 3kg 
of interdialytic weight gain and this type of weight gain is directly responsible for 
increased thirst and, interdialytic hypotension (Agarwal, 2006). In order to end this cycle 
interdialytic sodium delivery should be based on individual patient needs. The take away 
message is reinforcing the importance of the sodium-restricted diet in dialysis patients as 
another method to effectively control intradialytic fluid weight gain and hypertension.  
Researchers found that adherence to a 2 gm sodium diet would decrease 
interdialytic weight gain by controlling thirst and limiting weight gain may alleviate the 
large variations in BP and possibly prevent intradialytic hypotensive symptoms 
(Agarwal, 2006). Agarwal (2006) states a patient who follows a 2 gm sodium diet would 
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most likely have an interdialytic weight gain of 1.25kg over 48 hours and 1.9kg in 72 
hours. Sodium restriction is beneficial because it may assist in limiting large interdialytic 
weight gains and mitigates the large swings in blood pressures that may decrease 
incidences of intradialytic hypotensive symptoms (Agarwal, 2006). 
Hemoglobin 
The pre and post BVM hemoglobin (Hgb) mean was 12 mg/dl with a p value of 
.641, which was not statistically significant. However the Hgb values did meet national 
guidelines and recommendations from the NFK-KDOQI guidelines that target Hgb 
ranges between 10-12 g/dl for dialysis patients. The BVM utilizes the patient’s real time 
Hgb to estimate the patient’s extracellular status given Hgb variability changes in the 
patient’s fluid levels (Hlebovy, 2003).  
Limitations 
Limitations were identified in this study. All of the records reviewed were from 
patients at one freestanding outpatient hemodialysis unit chosen by a convenience 
sampling method. The sample size was small (N=42) and did not meet the number (50) 
mandated by the power analysis.  
The dialysis unit’s population of 45.2% Caucasian, 42.9% Hispanic/Latino, and 
7.1% African descent was not representative of the national average. This is seen as a 
limitation if results are to be applied nationally. The large Hispanic group may have been 
responsible for the larger percentage of diabetes mellitus and hypertension. The small 
percentage of African descent patients may have limited the power of the BVM 
intervention as various studies have found a higher prevalence of volume dependent 
hypertension among those of African descent (Kalantar-Zadeh et al.2009 & Baraz, 2010).  
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Another limitation was the inability to collect patient’s pre and post BVM glucose 
readings because the unit monitors Hemoglobin A1C levels four times a year in known 
diabetic patients only. There were also no current serum glucose levels. Elevated serum 
glucose levels may be a cause of excess ECV due to increased serum osmolarity.  
The limited use of the BVM in the facility used was also identified as a limitation. 
Optimally, the BVM should be used every 2-4 weeks on all patients to continue ongoing 
ECV management. It was also not possible to document the level of education of staff on 
the use of the BVM or the degree to which individual nurses used this data when making 
decisions during any one-dialysis event. The staff must be retrained and checked off on 
the proper use and interpretation of data obtained from the BVM in order to effectively 
use this technology to assess and manage ECV. Finally, research bias was a limitation. 
The bias of this author is that the primary etiology hypertension in most hemodialysis 
patients is resultant of excess ECV and diligent attention must be paid to this detail. 
These limitations have been acknowledged. 
Conclusion 
The findings of this study suggest the use of the use BVM is effective in the 
management of hypertension in hemodialysis patients with excess ECV. There were 
statically significant positive changes in post BVM pre dialysis systolic pressures, which 
were closer to the national guidelines goal of 140 mm/hg. A statically significant change 
was also found in pre vs. post BVM serum sodium. The data also revealed that the mean 
pre and post BVM diastolic blood pressure, sodium, and hemoglobin were all within the 
goals of national guidelines. This finding lends support of the belief that the use of BVM 
 55 
technology may assist with normalization of blood pressure and more effective 
management of excess ECV.  
Implications for Nursing 
The effectiveness of the use of the BVM to manage hypertensive hemodialysis 
patients is evident in this comparative descriptive study. Nephrologists and Advanced 
practitioners (Nurse practitioners [NP] and physician assistants [PA] will prescribe the 
dialysis prescription and consultation but the day-to-day management, including the safe 
execution of evidence based treatment, responsibility falls on the nurse. This study should 
help improve this process as these providers combine physical assessment parameters and 
BVM technology to formulate the protocol for specific patients.  
This also has implications for nurses actually supervising the dialysis event and 
making bedside decisions (often without the ARNP or physician provider present) as to 
when and how to end a session. Lindberg (2008) found that one in five HD patients were 
being dialyzed to an inadequate DW. A possible explanation may be lack of knowledge 
of the nursing staff about how to use the BVM data to make decisions about how to best 
achieve DW. In addition nurses may need education about how to use this data without 
fear of causing the patient undue discomfort because of removal of fluid either in a 
manner, which is too rapid possibly resulting in nausea, vomiting, or leg cramps.  
An expert dialysis nurse knows how the variables of intradialytic weight gain and 
rate of fluid removal (ultrafitration rate) are key quality indicators for qualitynephrology 
nursing care. They know how to (and actually do) assess these factors on a regular basis. 
This retrospective study did not look at individual clinical assessment parameters used by 
the nursing staff (such as edema, or adventitious lung sounds) and it is important to note 
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nursing support is critical to assisting patients in developing proficiency in certain skills 
and tasks.  
Due to the increasing prevalence of chronic kidney disease (CKD) and ESRD in 
the United States and excess ECV management is imperative to decrease patient 
morbidity and mortality. The belief that fluid overload is a normal condition in most HD 
patients is a paradigm that must be discarded in favor of a new paradigm that emphasizes 
cardiovascular disease is the leading cause of mortality with over hydration as a major 
contributing factor (Linberg, 2008). The nephrology nurse and the nephrology Advanced 
Practitioner have regular and frequent interactions with the HD patient and hence have an 
opportunity to educate the patient about fluid, sodium, and hypertension management 
(2008). It is the hope of this researcher that the findings will be used to imporve protocols 
to manage ECV in the HD patient. 
Advanced practice nurses in nephrology, in particular those with a doctorate in 
nursing practice (DNP), will be able to take the information from this study and improve 
routine evaluation of patients’ ECV status and possibly adjustment of the dry weight 
through the use of protocols. Lindberg (2008) observed that advanced practice nurses 
often provide expert care, which results in optimized patient self-management. DNP may 
take the reigns of to educate advanced practice nurses, nephrology nurses, and ancillary 
staff on the signs and symptoms of ECV excess. Effective ECV management is achieved 
ongoing assessment with the goal of getting the patient as close to normotension as 
possible while decreasing the patient’s pill burden by discontinuing antihypertensive 
medications as warranted.  
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Dialysis staff must be trained that if the patient begins to experience hypotension, 
cramps, and/or nausea and/or vomiting to notify the nursing staff or the advanced 
practitioner nurse to make adjustments to the rate of fluid removal, medications, and /or 
dry weight. All those involved in the care of the dialysis patient must be involved must 
empower the patient by providing ongoing education regarding ECV and blood pressure 
management along with information regarding sodium and fluid restrictions. 
Suggestions for Future Research 
Future research is recommended for excess ECV management in hypertensive HD 
patients with the hope of decreasing morbidity and mortality associated with 
cardiovascular disease. The same study may be duplicated in units with a population 
closer to the national average to better assess the use of the use of BVM technology in 
hypertensive hemodialysis patients in which secondary causes have been excluded. The 
BVM is expensive so there are limited quantities available in select HD units but a 
protocol in which BVM is used weekly may seek to decrease hospitalizations and 
morbidity and mortality rates. Research that would continue to reinforce the role of 
excess ECV in dialysis patients is needed to decrease morbidity and mortality in this 
vulnerable population. A much larger prospective study in which the glucose levels are 
measured in correlation with hypertension and increased ECV (either by hemoglobin 
A1C or serum glucose) may capture variables not captured in this study.  
The NKF-KDOQI guidelines (2006) state drugs that inhibit the renin-angiotensin 
system (RAS), such as angiotensin converting enzyme inhibitors (ACE-I) or angiotensin 
II-receptor blockers (ARB) are preferred in the management of hypertension in dialysis 
patients because they cause greater regression of left ventricular hypertrophy (LVH), 
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reduce sympathetic nerve activity, reduce pulse wave velocity, may improve endothelial 
function, and may reduce oxidative stress (Agarwal, 2007). A follow up study with a 
larger sample may examine if the findings of the BVM along with certain 
antihypertensive medications to assess which single medication or combination of 
medications will improve make no change, or possibly worsen patient outcomes. 
Summary 
The reported outcomes of this project are relevant to the management of 
hypertensive dialysis patients with excess ECV yet there is vast room for improvement in 
this arena. Individuals that will benefit from the outcomes of this study include 
physicians, advanced practice practitioners, nephrology nurses and ancillary staff who 
were unaware of the importance of excess ECV in the management of HTN in dialysis 
patients. Familiarity with the pathophysiology of HTN in this population will lead to 
decrease pill burden, decreased hospitalizations, and decreased morbidity and mortality. 
The outcomes revealed descriptive information about the management of ECV in 
hypertensive HD patients. Extrapolated information included the statistically significant 
reduction in pre dialysis systolic blood pressure and post BVM serum sodium. These 
findings may be used as the foundation for future works of research in dialysis patients 
and all those with issues of excess ECV such as those with heart and liver failure. 
  
 59 
APPE NDI X A : 2728 F O R M 
  
 60 
 61 
 62 
 63 
 64 
 
 65 
  
 66 
APPE NDI X B : D A T A C O L L E C T I O N T O O L 
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DIABETES  
Type II, adult-onset type or unspecified type diabetes  
Type I, juvenile type, ketosis prone diabetes  
CYSTIC/HEREDITARY/CONGENITAL DISEASES  
Polycystic kidneys, adult type (dominant)  
Polycystic, infantile (recessive)  
Medullary cystic disease, including nephronophthisis  
Tuberous sclerosis  
Hereditary nephritis, Alport’s syndrome  
Cystinosis  
Primary oxalosis  
Fabry’s disease  
Congenital nephrotic syndrome  
Drash syndrome, mesangial sclerosis  
Congenital obstructive uropathy  
Renal hypoplasia, dysplasia, oligonephronia  
Prune belly syndrome  
Hereditary/familial nephropathy  
GLOMERULONEPHRITIS  
Glomerulonephritis (GN)  
(histologically not examined)  
Focal glomerulosclerosis, focal sclerosing GN  
Membranous nephropathy  
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Membranoproliferative GN type 1, diffuse MPGN  
Dense deposit disease, MPGN type 2  
IgA nephropathy, Berger’s disease  
(Proven by immunofluorescence)  
IgM nephropathy  (proven by immunofluorescence)  
Rapidly progressive GN  
Goodpasture’s Syndrome  
Post infectious GN, SBE  
Other proliferative GN  
SECONDARY GN/VASCULITIS  
Lupus erythematosus, (SLE nephritis)  
Henoch-Schonlein syndrome  
Scleroderma  
Hemolytic uremic syndrome  
Polyarteritis  
Wegener’s granulomatosis  
Nephropathy due to heroin abuse and related drugs  
Vasculitis and its derivatives  
Secondary GN, other  
HYPERTENSION/LARGE VESSEL DISEASE  
Renal disease due to hypertension (no primary renal disease)  
Renal artery stenosis  
Renal artery occlusion  
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Cholesterol emboli, renal emboli  
INTERSTITIAL NEPHRITIS/PYELONEPHRITIS  
Analgesic abuse  
Radiation nephritis  
Lead nephropathy  
Nephropathy caused by other agents  
Gouty nephropathy  
Light chain nephropathy  
Amyloidosis  
NEOPLASMS/TUMORS  
Renal tumor (malignant)  
Urinary tract tumor (malignant)  
Renal tumor (benign)  
Urinary tract tumor (benign)  
Renal tumor (unspecified)  
Urinary tract tumor (unspecified)  
Lymphoma of kidneys  
Multiple myeloma   
Complication post bone marrow or other transplant  
MISCELLANEOUS CONDITIONS  
Sickle cell disease/anemia  
Sickle cell trait and other sickle cell (HbS/Hb other)  
Post partum renal failure  
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AIDS nephropathy  
Traumatic or surgical loss of kidney(s)  
Hepatorenal syndrome  
Tubular necrosis (no recovery)  
Other renal disorders  
Etiology uncertain  
Co-Morbid Conditions (Current or during last 10 years)  
Congestive heart failure  
Ischemic heart disease, CAD 
Myocardial infarction  
Cardiac arrest  
Cardiac dysrhythmia  
Pericarditis  
Cerebrovascular disease, CVA, TIA  
Peripheral vascular disease 
History of hypertension  
Diabetes (primary or contributing)  
Diabetes, currently on insulin  
Chronic obstructive pulmonary disease  
Tobacco use (current smoker)  
Malignant neoplasm, Cancer  
Alcohol dependence  
Drug dependence 
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HIV positive status 
AIDS  
Amputation  
Inability to ambulate  
Inability to transfer  
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